May 2018

Heydt: #ampeurope2018 2 ROS1 fusions not det by FISH, orthog. confirmed. 1 ROS1 fusion not det by FISH, not confirmed 'thus prob FP'

4:36am May 1st 2018 via Twitter Web Client

Heydt: #ampeurope2018 From 24 samples - 22/24 as low as 9 ng. 2 failed; 1 high level MET amp; low- int-level undetected

4:32am May 1st 2018 via Twitter Web Client

Heydt: #ampeurope2018 Shows biomarkers, Rx options, and MH Guide Reporting. (GenomeWeb https://t.co/U5Fjij5kzu )

4:30am May 1st 2018 via Twitter Web Client

Carina Heydt (Univ Cologee DE) Illumina workshop #ampeurope2018 Shows TST 170 to Variant Interpeter app. They use Molecular Health guide

4:29am May 1st 2018 via Twitter Web Client

Q: Type of sample? Bernards: #ampeurope2018 FFPE, even FNAs.

3:32am May 1st 2018 via Twitter Web Client

A3 Bernards: #ampeurope2018 The catch-22 of reimbursement and standard of care.

3:31am May 1st 2018 via Twitter Web Client

A2: Bernards: #ampeurope2018 Hard to validate all 70 genes; time and $. 'The US FDA has figured it out... EU has no consensus...'

3:31am May 1st 2018 via Twitter Web Client

Q: WT w/DNA is simple. How to std-ize RNA in the lab? Bernards: #ampeurope2018 Now have RNA-seq version of MammaPrint on MiSeq.

3:29am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Concludes - examples of DNA-based therapies, but prognosis by GEx, subtypes by GEx, and pathways for classification

3:20am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 A case where the luminal signal is higher than the HER2, even though FISH indicates HER2+/ER+. NBRST study...

3:17am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 But 23% of pt classified into different subgroup cp to IHC/FISH. 1/2 FISH+ for HER2+/ER+ are BP luminal.

3:16am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 He founded Agendia, with Blueprint, dividing to luminal, HER-2 type, Basal-type. Luminal goes onto MammaPrint

3:15am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Pharma has the fear/greed factor; sound rational for TNBC. 9 mos at Genentech: "The marketing people always win."

3:14am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Shows K-M w/BRCA1-like tumors that clearly benefit. Shows BRCA1-like tumors w/77 gene signature

3:11am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Hi-dose chemo, high cross-linking, same effect as PARPi that needs HEJR mechanism.

3:10am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 'For AZ, a billion dollar question'. (!) 1/3 w/promoter methylation, unexpressed.

3:09am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Doing aCGH, a spec pattern of CN gain/loss when cp to sporatic TN cancer. Can find 3x CN pattern but BRCA1 wt

3:08am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Shows this PD-1 blockade with MMR https://t.co/aWXuwqo4hy and shows this: MSI-like, for CRC https://t.co/FbgL7kTii8

3:01am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 'Mutation analysis is not the be-all, end-all for personalized medicine'. 'And I'll continue beating this horse...'

2:59am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Shows K-M of BRAF-like colon ca pts, w/poor outcome but sens to vinorelbine as possible Rx strategy.

2:58am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Some colon tumors have the gene sig of BRAF mutant tumors, but lack BRAF mut. https://t.co/2N893BdlQa

2:56am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 And EGFRi not useful for melanoma, b/c not expressed. A single gene expressed making the response different

2:54am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Finds 'massively interesting as a scientist'. Synthetic lethality screen: had to inhibit EGFR too along w/BRAF.

2:52am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Shows famous Wagle photo: 'the poster child of personalized medicine'. BRAF mutant first response very good...

2:49am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Reverting EMT via chemoRx response of TGF-beta. MammaPrint: 70 gene sig, back from '02 to assess risk in br ca

2:47am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Makes the case for Br, CRC, GB, Panc subtypes 'cannot be identified through DNA analyses only'

2:46am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 The need to analyze RNA; CRC has 3-5 intrinsic subtypes; shows 3 via gene expression and K-M curves

2:44am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 'We like to complain in Holland in general.' Commentary: colon cancer subtypes have different biology.

2:42am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 'A case of Irrational Exuberance?' '16 ref https://t.co/LDKyUTrMwC And Vinay Prasad soon after, NEJM Tannock

2:42am May 1st 2018 via Twitter Web Client

Bernards: #ampeurope2018 Changing views of NSCLC: from a morphology-centric to a genome-centric view. Shows long list of genes/drugs

2:40am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 (Here's the ASCO 2015 PDF of the Lynch Syndrome FSP vaccine from Oryx https://t.co/G5BY1biUlc )

2:36am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Have developed a FSP vaccine - ASCO 15 results https://t.co/8nVsJ5r2yG

2:32am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Three molecular pathways model '18 ref https://t.co/aBgjJkyHhe for CRC in Lynch

2:20am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Asking when MMR- deficiency a late event; correlatoin of MMR w/size, grade of adenomas.

2:18am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Colonoscopy does not prevent all colon cancer in Lynch; 15% risk in 10y. https://t.co/K8jLvz9UzU

2:17am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Warthin's seamstress, published a family tree in 1913. Cancer risk for Lynch - penetrance not so high.

2:14am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 15% of CRC is MSI-H; of that 3/4 is sporadic, MLH1 promoter methylated. Knudson's two-hit theory w/Lynch Syndrome

2:12am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Mutational load from '13 https://t.co/CXv7Pq01rJ Rationale why MSI-H is a readout for sporadic CRC

2:11am May 1st 2018 via Twitter Web Client

Ahadova: #ampeurope2018 Frameshifted peptides (FSP) are new to the immune system. Shows image from https://t.co/1nOYblvbOi

2:10am May 1st 2018 via Twitter Web Client